Karin A. Herrmann
Papers
1
Total Citations
28
H-Index
1
About
Karin A. Herrmann is a leading radiation oncologist whose research focuses on the intersection of stereotactic ablative radiotherapy (SABR) and systemic therapy for gynecologic malignancies. Her major contributions center on developing innovative, less invasive treatment paradigms for persistent or recurrent gynecologic cancers, particularly through the integration of chemotherapy with high-precision radiosurgery. Her landmark Phase I trial, which has garnered 28 citations, established the foundational safety profile of combining carboplatin and gemcitabine chemotherapy with abdominopelvic robotic SABR for palliative treatment—a critical step toward offering patients more targeted, less toxic options. This work demonstrates Herrmann’s commitment to advancing personalized, multimodality approaches that improve quality of life while maintaining therapeutic efficacy. Her research is instrumental in shaping modern palliative strategies for women with challenging recurrent disease, and her findings continue to inform subsequent clinical protocols and prospective trials in radiation oncology.
Research Focus
Key Achievements
Top Papers
- 1